zanubrutinib versus rituximab-based chemoimmunotherapy in waldenström's macroglobulinemia
Published 3 years ago • 956 plays • Length 4:15Download video MP4
Download video MP3
Similar videos
-
3:16
aspen: zanubrutinib vs ibrutinib in waldenström's macroglobulinemia
-
0:58
updates from the phase iii sequoia trial: zanubrutinib vs. br in the treatment of patients with cll
-
1:44
the efficacy of zanubrutinib versus ibrutinib in patients with wm harboring various mutations
-
5:20
constantine tam: comparing zanubrutinib with ibrutinib in waldenström macroglobulinemia
-
1:18
celestial-tncll: ongoing phase iii study of sonrotoclax zanubrutinib vs ven obi for tn cll
-
1:06
zanubrutinib in patients with b-cell malignancies who are acalabrutinib-intolerant
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
7:37
living with waldenstrom's with bob rupert
-
4:33
brawm: bendamustine, rituximab and acalabrutinib for waldenström’s macroglobulinemia
-
3:48
impressive data: zanubrutinib for waldenström’s macroglobulinemia
-
2:04
updated long-term follow-up of sequoia: zanubrutinib vs bendamustine-rituximab in untreated cll/sll
-
35:47
zanubrutinib for the treatment of waldenstrom's macroglobulinemia
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
0:47
alpine results: zanubrutinib vs. ibrutinib in cll
-
1:21
response-adapted therapy with copanlisib and rituximab for previously untreated fl
-
0:48
martin barrett on intravenous versus subcutaneous rituximab
-
1:20
health-related quality of life with zanubrutinib versus ibrutinib for patients with r/r cll
-
1:55
the alpine trial shows improved outcomes with zanubrutinib versus ibrutinib in r/r cll
-
1:13
alpine trial update: zanubrutinib continues to show superior efficacy to ibrutinib in cll
-
1:08
post hoc analysis comparing the safety profile of zanubrutinib vs ibrutinib in b-cell malignancies
-
2:07
sequoia: zanubrutinib vs br in treatment-naïve cll/sll